Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Design of a novel class of protein-based magnetic resonance imaging contrast agents for the molecular imaging of cancer biomarkers.

Xue S, Qiao J, Pu F, Cameron M, Yang JJ.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013 Mar-Apr;5(2):163-79. doi: 10.1002/wnan.1205. Epub 2013 Jan 17. Review.

2.

Design of ProCAs (protein-based Gd(3+) MRI contrast agents) with high dose efficiency and capability for molecular imaging of cancer biomarkers.

Xue S, Qiao J, Jiang J, Hubbard K, White N, Wei L, Li S, Liu ZR, Yang JJ.

Med Res Rev. 2014 Sep;34(5):1070-99. doi: 10.1002/med.21313. Epub 2014 Mar 11. Review.

PMID:
24615853
3.

Towards the Molecular Imaging of Prostate Cancer Biomarkers Using Protein-based MRI Contrast Agents.

Pu F, Xue S, Qiao J, Patel A, Yang JJ.

Curr Protein Pept Sci. 2016;17(6):519-33. Review.

PMID:
26721404
4.

Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents.

Qiao J, Xue S, Pu F, White N, Jiang J, Liu ZR, Yang JJ.

J Biol Inorg Chem. 2014 Feb;19(2):259-70. doi: 10.1007/s00775-013-1076-3. Epub 2013 Dec 24. Review.

5.

GRPR-targeted Protein Contrast Agents for Molecular Imaging of Receptor Expression in Cancers by MRI.

Pu F, Qiao J, Xue S, Yang H, Patel A, Wei L, Hekmatyar K, Salarian M, Grossniklaus HE, Liu ZR, Yang JJ.

Sci Rep. 2015 Nov 18;5:16214. doi: 10.1038/srep16214.

6.

Chemistry of tumour targeted T1 based MRI contrast agents.

Kamaly N, Miller AD, Bell JD.

Curr Top Med Chem. 2010;10(12):1158-83. Review.

PMID:
20388110
7.

Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action.

Caravan P.

Acc Chem Res. 2009 Jul 21;42(7):851-62. doi: 10.1021/ar800220p.

PMID:
19222207
8.

Gd-hydroxypyridinone (HOPO)-based high-relaxivity magnetic resonance imaging (MRI) contrast agents.

Datta A, Raymond KN.

Acc Chem Res. 2009 Jul 21;42(7):938-47. doi: 10.1021/ar800250h. Review.

9.

Gadolinium-based contrast agents for magnetic resonance cancer imaging.

Zhou Z, Lu ZR.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013 Jan-Feb;5(1):1-18. doi: 10.1002/wnan.1198. Epub 2012 Oct 9. Review.

10.

Current limitations of molecular magnetic resonance imaging for tumors as evaluated with high-relaxivity CD105-specific iron oxide nanoparticles.

Dassler K, Roohi F, Lohrke J, Ide A, Remmele S, Hütter J, Pietsch H, Pison U, Schütz G.

Invest Radiol. 2012 Jul;47(7):383-91. doi: 10.1097/RLI.0b013e31824c5a57.

PMID:
22659596
11.

Fabrication and evaluation of tumor-targeted positive MRI contrast agent based on ultrasmall MnO nanoparticles.

Huang H, Yue T, Xu K, Golzarian J, Yu J, Huang J.

Colloids Surf B Biointerfaces. 2015 Jul 1;131:148-54. doi: 10.1016/j.colsurfb.2015.04.047. Epub 2015 Apr 29.

PMID:
25982318
12.

Design of a modular protein-based MRI contrast agent for targeted application.

Grum D, Franke S, Kraff O, Heider D, Schramm A, Hoffmann D, Bayer P.

PLoS One. 2013 Jun 6;8(6):e65346. doi: 10.1371/journal.pone.0065346. Print 2013.

13.

Gadolinium chelate with DO3A conjugated 2-(diphenylphosphoryl)-ethyldiphenylphosphonium cation as potential tumor-selective MRI contrast agent.

Chandrasekharan P, Yong CX, Poh Z, He T, He Z, Liu S, Robins EG, Chuang KH, Yang CT.

Biomaterials. 2012 Dec;33(36):9225-31. doi: 10.1016/j.biomaterials.2012.08.071. Epub 2012 Sep 29.

PMID:
23026708
14.

Protein-based MRI contrast agents for molecular imaging of prostate cancer.

Wei L, Li S, Yang J, Ye Y, Zou J, Wang L, Long R, Zurkiya O, Zhao T, Johnson J, Qiao J, Zhou W, Castiblanco A, Maor N, Chen Y, Mao H, Hu X, Yang JJ, Liu ZR.

Mol Imaging Biol. 2011 Jun;13(3):416-423. doi: 10.1007/s11307-010-0342-9.

15.

MR molecular imaging of prostate cancer with a small molecular CLT1 peptide targeted contrast agent.

Wu X, Lindner D, Yu GP, Brady-Kalnay S, Lu ZR.

J Vis Exp. 2013 Sep 3;(79). doi: 10.3791/50565.

16.

Responsive MRI agents for sensing metabolism in vivo.

De Leon-Rodriguez LM, Lubag AJ, Malloy CR, Martinez GV, Gillies RJ, Sherry AD.

Acc Chem Res. 2009 Jul 21;42(7):948-57. doi: 10.1021/ar800237f. Review.

17.

Integrating Anatomic and Functional Dual-Mode Magnetic Resonance Imaging: Design and Applicability of a Bifunctional Contrast Agent.

Ni D, Shen Z, Zhang J, Zhang C, Wu R, Liu J, Yi M, Wang J, Yao Z, Bu W, Shi J.

ACS Nano. 2016 Mar 22;10(3):3783-90. doi: 10.1021/acsnano.6b00462. Epub 2016 Feb 26.

PMID:
26910513
18.

Magnetic resonance in the era of molecular imaging of cancer.

Gore JC, Manning HC, Quarles CC, Waddell KW, Yankeelov TE.

Magn Reson Imaging. 2011 Jun;29(5):587-600. doi: 10.1016/j.mri.2011.02.003. Epub 2011 Apr 27. Review.

19.

A novel gadolinium-based trimetasphere metallofullerene for application as a magnetic resonance imaging contrast agent.

Adiseshaiah P, Dellinger A, MacFarland D, Stern S, Dobrovolskaia M, Ileva L, Patri AK, Bernardo M, Brooks DB, Zhou Z, McNeil S, Kepley C.

Invest Radiol. 2013 Nov;48(11):745-54. doi: 10.1097/RLI.0b013e318294de5d.

PMID:
23748228
20.

HER2 targeted molecular MR imaging using a de novo designed protein contrast agent.

Qiao J, Li S, Wei L, Jiang J, Long R, Mao H, Wei L, Wang L, Yang H, Grossniklaus HE, Liu ZR, Yang JJ.

PLoS One. 2011 Mar 24;6(3):e18103. doi: 10.1371/journal.pone.0018103.

Supplemental Content

Support Center